Protocol-defined asthma exacerbations during the placebo-controlled period
| Placebo (n=116) | Lebrikizumab 37.5 mg (n=117) | Lebrikizumab 125 mg (n=112) | Lebrikizumab 250 mg (n=118) | Lebrikizumab dose groups combined (n=347) | |
|---|---|---|---|---|---|
| Periostin-high patients (≥50 ng/mL), n | 42 | 57 | 43 | 53 | 153 |
| Total number of exacerbations | 21 | 5 | 5 | 19 | 29 |
| Total patient-years | 20.7 | 26.6 | 21.2 | 24.1 | 72.0 |
| Exacerbation rate per year | 1.01 | 0.19 | 0.24 | 0.79 | 0.40 |
| Rate reduction vs placebo | |||||
| Absolute rate reduction | – | 0.82 | 0.77 | 0.22 | 0.61 |
| Percentage rate reduction (95% CI) | – | 81% (35 to 97) | 77% (26 to 95) | 22% (−62 to 63) | 60% (18 to 80) |
| Periostin-low patients (<50 ng/mL), n | 74 | 60 | 69 | 65 | 194 |
| Total number of exacerbations | 17 | 9 | 20 | 14 | 43 |
| Total patient-years | 35.4 | 28.1 | 35.5 | 30.7 | 94.3 |
| Exacerbation rate per year | 0.48 | 0.32 | 0.56 | 0.46 | 0.46 |
| Rate reduction vs placebo | |||||
| Absolute rate reduction | – | 0.16 | −0.08 | 0.02 | 0.02 |
| Percentage rate reduction (95% CI) | – | 33% (−53 to 73) | −17% (−141 to 42) | 5% (−114 to 59) | 5% (−81 to 47) |